Panobinostat (LBH589)

Catalog No.S1030 Synonyms: NVP-LBH589

Molecular Weight(MW): 349.43

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.

Cited by 209 Publications

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cancer Cell, 2019, 36(5):528-544

PubMed: 31631026 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):782-797

PubMed: 31085178 ( click the link to review the publication )

Nat Immunol, 2019, 20(7):835-851

PubMed: 31160797 ( click the link to review the publication )

Nat Med, 2018, 24(11):1752-1761

PubMed: 30349086 ( click the link to review the publication )

Cell, 2018, 173(6):1413-1425

PubMed: 29754815 ( click the link to review the publication )

Nat Genet, 2018, 50(10):1442-1451

PubMed: 30224647 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

Cancer Cell, 2017, 31(5):635-652

PubMed: 28434841 ( click the link to review the publication )

Cancer Cell, 2016, 29(3):311-323

PubMed: 26977882 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):264-73

PubMed: 25542447 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):264-73

PubMed: 25542447 ( click the link to review the publication )

Cell, 2014, 159(5):1110-25

PubMed: 25416949 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(3):255-65

PubMed: 21258344 ( click the link to review the publication )

Cell Res, 2019, 29(4):286-304

PubMed: 30631154 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3319

PubMed: 31346162 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31227503 ( click the link to review the publication )

Leukemia, 2019, 10.1038/s41375-019-0525-6

PubMed: 31358854 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2019, 116(26):12986-12995

PubMed: 31182587 ( click the link to review the publication )

Neuro Oncol, 2019, 10.1093/neuonc/noz215

PubMed: 31711240 ( click the link to review the publication )

Cancer Immunol Res, 2019, 7(2):230-243

PubMed: 30563830 ( click the link to review the publication )

Cancer Res, 2019, 79(11):2947-2961

PubMed: 30987999 ( click the link to review the publication )
Haematologica, 2019, 10.3324/haematol.2018.211110

PubMed: 30846494 ( click the link to review the publication )

Clin Infect Dis, 2019, 10.1093/cid/ciz108

PubMed: 30753360 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):33

PubMed: 30728070 ( click the link to review the publication )

Theranostics, 2019, 9(2):540-553

PubMed: 30809292 ( click the link to review the publication )

Cell Rep, 2019, 29(9):2783-2795

PubMed: 31775045 ( click the link to review the publication )

Elife, 2019, 10.7554/eLife.44306

PubMed: 31050342 ( click the link to review the publication )

Oncogene, 2019, 38(15):2690-2705

PubMed: 30538293 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):185

PubMed: 31053152 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31561534 ( click the link to review the publication )

PLoS Pathog, 2019, 15(8):e1007991

PubMed: 31425551 ( click the link to review the publication )

Breast Cancer Res, 2019, 21(1):134

PubMed: 31801577 ( click the link to review the publication )

Acta Pharm Sin B, 2019, 9(5):937-951

PubMed: 31649844 ( click the link to review the publication )

Front Immunol, 2019, 9:3162

PubMed: 30723480 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):900-908

PubMed: 30824609 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(1):185-195

PubMed: 30301863 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(8):1439-1450

PubMed: 31142662 ( click the link to review the publication )

Biochim Biophys Acta Mol Basis Dis, 2019, 1865(6):1666-1676

PubMed: 30954557 ( click the link to review the publication )

J Biomed Nanotechnol, 2019, 15(5):979-992

PubMed: 30890229 ( click the link to review the publication )

Epigenetics, 2019, 10.1080/15592294.2019.1656156

PubMed: 31423932 ( click the link to review the publication )

AIDS, 2019, 33(2):199-209

PubMed: 30562171 ( click the link to review the publication )

Biomolecules, 2019, 9(5)

PubMed: 31083537 ( click the link to review the publication )

Mol Pharm, 2019, 16(5):1813-1826

PubMed: 30883132 ( click the link to review the publication )

J Cell Physiol, 2019, 234(10):18970-18984

PubMed: 30916359 ( click the link to review the publication )

Eur J Nutr, 2019, 10.1007/s00394-019-01925-6

PubMed: 30762097 ( click the link to review the publication )
Antimicrob Agents Chemother, 2019, 63(2)

PubMed: 30455231 ( click the link to review the publication )

Epigenetics Chromatin, 2019, 12(1):18

PubMed: 30871586 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(12)

PubMed: 31234549 ( click the link to review the publication )

J Biol Chem, 2019, 294(12):4437-4449

PubMed: 30670592 ( click the link to review the publication )

Apoptosis, 2019, 24(1-2):184-197

PubMed: 30498998 ( click the link to review the publication )

Mol Carcinog, 2019, 58(12):2230-2240

PubMed: 31478563 ( click the link to review the publication )

Mol Carcinog, 2019, 58(2):234-246

PubMed: 30303565 ( click the link to review the publication )

Virus Res, 2019, 269:197631

PubMed: 31136823 ( click the link to review the publication )

Mol Genet Genomic Med, 2019, 7(5):e613

PubMed: 30891950 ( click the link to review the publication )

Childs Nerv Syst, 2019, 35(5):823-831

PubMed: 30815722 ( click the link to review the publication )

J Nanobiotechnology, 2019, 17(1):69

PubMed: 31113488 ( click the link to review the publication )

J Virus Erad, 2019, 5(3):133-137

PubMed: 31700655 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4866

PubMed: 30451831 ( click the link to review the publication )

Nat Commun, 2018, 9(1):764

PubMed: 29472538 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(16):3941-3954

PubMed: 29764852 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(1):120-129.

PubMed: 29066507 ( click the link to review the publication )

Cancer Res, 2018, 78(5):1155-1168

PubMed: 29259009 ( click the link to review the publication )

Cancer Res, 2018, 78(14):4007-4021

PubMed: 29760046 ( click the link to review the publication )

Int J Cancer, 2018, 143(6):1388-1401

PubMed: 29633255 ( click the link to review the publication )

Oncogene, 2018, 37(6):722-731

PubMed: 29059175 ( click the link to review the publication )

Cancer Lett, 2018, 417:152-160

PubMed: 29306016 ( click the link to review the publication )

Sci Signal, 2018, 11(557)

PubMed: 30459282 ( click the link to review the publication )

EBioMedicine, 2018, 28:80-89

PubMed: 29396295 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):944

PubMed: 30237504 ( click the link to review the publication )
Mol Cancer Ther, 2018, 17(12):2767-2779

PubMed: 30232145 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(8):1705-1716

PubMed: 29748211 ( click the link to review the publication )

Cell Oncol (Dordr), 2018, 41(2):201-212

PubMed: 29260509 ( click the link to review the publication )

J Immunol, 2018, 201(3):1086-1096

PubMed: 29914885 ( click the link to review the publication )

J Virol, 2018, 92(13)

PubMed: 29643247 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(8)

PubMed: 30081552 ( click the link to review the publication )

Sci Rep, 2018, 8(1):9472

PubMed: 29930256 ( click the link to review the publication )

Biomed Pharmacother, 2018, 100:509-520

PubMed: 29494986 ( click the link to review the publication )

J Cell Biochem, 2018, 119(5):4193-4204

PubMed: 29274289 ( click the link to review the publication )

J Ethnopharmacol, 2018, 211:267-277

PubMed: 28970153 ( click the link to review the publication )

Exp Cell Res, 2018, 363(2):196-207

PubMed: 29317217 ( click the link to review the publication )

PLoS One, 2018, 13(12):e0208147

PubMed: 30592723 ( click the link to review the publication )

Dis Markers, 2018, 2018:3810108

PubMed: 30647797 ( click the link to review the publication )

Cell Biochem Funct, 2018, 36(8):398-407

PubMed: 30484863 ( click the link to review the publication )

Anticancer Drugs, 2018, 29(1):61-74

PubMed: 29049036 ( click the link to review the publication )

Oncotarget, 2018, 9(92):36530-36541

PubMed: 30559935 ( click the link to review the publication )

Oncotarget, 2018, 9(5):6450-6462

PubMed: 29464084 ( click the link to review the publication )

F1000Res, 2018, 7:1906

PubMed: 30881689 ( click the link to review the publication )

Oncotarget, 2018, 9(47):28586-28598

PubMed: 29983882 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2018, 100(1):174-187

PubMed: 29107335 ( click the link to review the publication )

Nat Commun, 2017, 8(1):728

PubMed: 28959017 ( click the link to review the publication )

Cancer Res, 2017, 77(11):3027-3039

PubMed: 28363998 ( click the link to review the publication )

Int J Cancer, 2017, 141(9):1921-1931

PubMed: 28710768 ( click the link to review the publication )

Arch Toxicol, 2017, 91(5):2191-2208

PubMed: 27807597 ( click the link to review the publication )
Arch Toxicol, 2017, 91(1):365-391

PubMed: 27015953 ( click the link to review the publication )

Arch Toxicol, 2017, 91(2):839-864

PubMed: 27188386 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(2):285-299

PubMed: 27980108 ( click the link to review the publication )

Br J Haematol, 2017, 178(5):728-738

PubMed: 28480959 ( click the link to review the publication )

Epigenetics, 2017, 12(2):105-112

PubMed: 27935420 ( click the link to review the publication )

Int J Nanomedicine, 2017, 12:1385-1399

PubMed: 28260886 ( click the link to review the publication )

J Biol Chem, 2017, 292(9):3683-3691

PubMed: 28087699 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(2):211-220

PubMed: 28860353 ( click the link to review the publication )

Mol Biol Cell, 2017, 28(26):3756-3772

PubMed: 29074567 ( click the link to review the publication )

Exp Cell Res, 2017, 350(1):218-225

PubMed: 27914787 ( click the link to review the publication )

Int J Parasitol Drugs Drug Resist, 2017, 7(1):42-50

PubMed: 28107750 ( click the link to review the publication )

PLoS One, 2017, 12(1):e0169485

PubMed: 28052119 ( click the link to review the publication )

Horm Cancer, 2017, 8(4):257-267

PubMed: 28516379 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:11-22

PubMed: 27761810 ( click the link to review the publication )

Blood Adv, 2017, 1(19):1575-1583

PubMed: 29296798 ( click the link to review the publication )

Genom Data, 2017, 12:14-16

PubMed: 28239551 ( click the link to review the publication )

JCI Insight, 2017, 2(1):e85811

PubMed: 28097226 ( click the link to review the publication )

JCI Insight, 2017, 2(6):e90196

PubMed: 28352655 ( click the link to review the publication )

Oncotarget, 2017, 9(3):3908-3921

PubMed: 29423093 ( click the link to review the publication )

Oncotarget, 2017, 8(18):30019-30029

PubMed: 28415789 ( click the link to review the publication )

Oncotarget, 2017, 8(34):56747-56757

PubMed: 28915627 ( click the link to review the publication )

Oncotarget, 2017, 8(44):77254-77267

PubMed: 29100385 ( click the link to review the publication )

Oncotarget, 2017, 8(55):94569-94579

PubMed: 29212250 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:127-148

PubMed: 27761818 ( click the link to review the publication )
Blood, 2016, 127(10):1325-35

PubMed: 26668133 ( click the link to review the publication )

Nucleic Acids Res, 2016, 45(3):1159-1176

PubMed: 28180300 ( click the link to review the publication )

EMBO Mol Med, 2016, 8(2):117-38

PubMed: 26681773 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(10):2534-44

PubMed: 26733615 ( click the link to review the publication )

Int J Cancer, 2016, 139(1):194-204

PubMed: 26914605 ( click the link to review the publication )

Oncogene, 2016, 35(46):6026-6037

PubMed: 27157610 ( click the link to review the publication )

Mol Oncol, 2016, 10(5):735-750

PubMed: 26775640 ( click the link to review the publication )

Mol Ther Methods Clin Dev, 2016, 3:16003

PubMed: 27626039 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Sci Rep, 2016, 6:38407

PubMed: 27910927 ( click the link to review the publication )

J Biol Chem, 2016, 291(16):8745-55

PubMed: 26912657 ( click the link to review the publication )

Biomed Pharmacother, 2016, 84:1393-1405

PubMed: 27802904 ( click the link to review the publication )

Retrovirology, 2016, 13(1):36

PubMed: 27206407 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2016, 142(11):2263-73

PubMed: 27576506 ( click the link to review the publication )

Am J Transl Res, 2016, 8(9):3893-3902

PubMed: 27725868 ( click the link to review the publication )

PLoS One, 2016, 11(2):e0148912

PubMed: 26859414 ( click the link to review the publication )

Leuk Lymphoma, 2016, 57(11):2644-52

PubMed: 26980288 ( click the link to review the publication )

JCI Insight, 2016, 1(5):e85061

PubMed: 27699258 ( click the link to review the publication )

Ann Rheum Dis, 2015, 10.1136/annrheumdis-2014-206258

PubMed: 25589513 ( click the link to review the publication )

Biomaterials, 2015, 73:110-9

PubMed: 26406451 ( click the link to review the publication )

Blood Cancer J, 2015, 5:e312

PubMed: 25978432 ( click the link to review the publication )

J Med Chem, 2015, 58(2):785-800

PubMed: 25490700 ( click the link to review the publication )

J Med Chem, 2015, 58(2):785-800

PubMed: ( click the link to review the publication )

Arch Toxicol, 2015, 89(9):1599-618

PubMed: 26272509 ( click the link to review the publication )
Mol Oncol, 2015, 9(7):1447-1457

PubMed: 25957812 ( click the link to review the publication )

Mol Pharm, 2015, 12(7):2469-76

PubMed: 26030093 ( click the link to review the publication )

Sci Rep, 2015, 5:16445

PubMed: 26563568 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2015, 309(12):L1410-9

PubMed: 26498249 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: 25540204 ( click the link to review the publication )

J Biol Chem, 2015, 290(49):29478-92

PubMed: 26491017 ( click the link to review the publication )

J Biol Chem, 2015, 10.1074.jbc.M114.624361

PubMed: 25737447 ( click the link to review the publication )

J Biol Chem, 2015, 290(49):29478-92

PubMed: 26491017 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(12):1784-93

PubMed: 26529495 ( click the link to review the publication )

Int J Parasitol Drugs Drug Resist, 2015, 5(3):117-26

PubMed: 26199860 ( click the link to review the publication )

PLoS One, 2015, 10(7):e0126566

PubMed: 26176219 ( click the link to review the publication )

PLoS One, 2015, 10(8):e0134426

PubMed: 26247786 ( click the link to review the publication )

Pediatr Blood Cancer, 2015, 62(1):52-9

PubMed: 25308916 ( click the link to review the publication )

Pediatr Blood Cancer, 2015, 62(1):52-9

PubMed: 25308916 ( click the link to review the publication )

Exp Hematol, 2015, 43(6):448-61

PubMed: 25704054 ( click the link to review the publication )

Oncotarget, 2015, 6(19):17698-712

PubMed: 25989842 ( click the link to review the publication )

Western University, 2015, Western University

PubMed: ( click the link to review the publication )

Oncotarget, 2015, 6(25):21507-21

PubMed: 26087189 ( click the link to review the publication )

Oncotarget, 2015, 6(4):2088-100

PubMed: 25576920 ( click the link to review the publication )

Cancer Lett, 2014, 356(2 Pt B):656-68

PubMed: 25458954 ( click the link to review the publication )

PLoS Pathog, 2014, 10(4):e1004071

PubMed: 24722454 ( click the link to review the publication )

PLoS Pathog, 2014, 10(8):e1004287

PubMed: 25122219 ( click the link to review the publication )

Anal Chem, 2014, 86(10):4642-7

PubMed: 24559101 ( click the link to review the publication )
Br J Cancer, 2014, 111(2):281-91

PubMed: 24946002 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Br J Haematol, 2014, 167(5):639-50

PubMed: 25155625 ( click the link to review the publication )

J Immunol, 2014, 193(3):1333-43

PubMed: 24973453 ( click the link to review the publication )

Mol Carcinog, 2014, 53(9):722-35

PubMed: 23475695 ( click the link to review the publication )

BMC Cancer, 2014, 14:17

PubMed: 24418474 ( click the link to review the publication )

PLoS One, 2014, 9(11):e113341

PubMed: 25409334 ( click the link to review the publication )

PLoS One, 2014, 10(8):e1004287

PubMed: 25122219 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 452(3):649-54

PubMed: 25193706 ( click the link to review the publication )

Curr Pharm Desigh, 2014, 20(11):1874-80

PubMed: 23888956 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822

PubMed: 24986420 ( click the link to review the publication )

Nat Commun, 2013, 4:2735

PubMed: 24193185 ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(12):6018-33

PubMed: 23625969 ( click the link to review the publication )

Leukemia, 2013, 27(6):1291-300

PubMed: 23411464 ( click the link to review the publication )

Cell Rep, 2013, 5(6):1679-89

PubMed: 24360956 ( click the link to review the publication )

Cancer Lett, 2013, 329(1):17-26

PubMed: 22995071 ( click the link to review the publication )

Breast Cancer Res, 2013, 15(4):R58

PubMed: 23879992 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e951

PubMed: 24309938 ( click the link to review the publication )

Br J Haematol, 2013, 162(4):559-62

PubMed: 23692150 ( click the link to review the publication )

Radiother Oncol, 2013, 108(3):429-33

PubMed: 23932191 ( click the link to review the publication )

AIDS, 2013, 27(18):2853-62

PubMed: 24189584 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2013, 139(9):1507-14

PubMed: 23824064 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 71(5):1325-34

PubMed: 23515752 ( click the link to review the publication )

PLoS One, 2013, 8(8):e74253

PubMed: 23991216 ( click the link to review the publication )
PLoS One, 2013, 8(11):e79106

PubMed: 24244429 ( click the link to review the publication )

PLoS One, 2013, 8(9):e76662

PubMed: 24098799 ( click the link to review the publication )

PLoS One, 2013, 8(7):e69992

PubMed: 23922886 ( click the link to review the publication )

J Thromb Thrombolysis, 2013, 35(2):185-92

PubMed: 23229086 ( click the link to review the publication )

Theriogenology, 2013, 80(6):630-5

PubMed: 23866857 ( click the link to review the publication )

Protein Expr Purif, 2013, 92(1):119-127

PubMed: 24056254 ( click the link to review the publication )

Genet Mol Res, 2013, 12(4):5405-13

PubMed: 24301913 ( click the link to review the publication )

The University of Western Ontario, 2013, CHAE YOUNG HAN

PubMed: ( click the link to review the publication )

Obstet Gynecol Int, 2013, 2013:828165

PubMed: 24381593 ( click the link to review the publication )

Blood, 2012, 119(6):1450-8

PubMed: 22144178 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(2):408-16

PubMed: 22038994 ( click the link to review the publication )

Breast Cancer Res Tr, 2012, 131(3):777-89

PubMed: 21452019 ( click the link to review the publication )

J Neurooncol, 2012, 110(3):335-48

PubMed: 23054560 ( click the link to review the publication )

Acta Neuropathol, 2011, 122(5):637-50

PubMed: 21863243 ( click the link to review the publication )

PLoS One, 2011, 6(2):e17138

PubMed: 21359182 ( click the link to review the publication )

Sci Signal, 2010, 3(146):ra80

PubMed: 21045206 ( click the link to review the publication )

Biochem Bioph Res Co, 2010, 391(4):1748-51

PubMed: 20043870 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.

Targets

HDAC (MOLT-4 cells) ^[1]	HDAC (Reh cells) ^[1]
5 nM	20 nM

In vitro

LBH589 induces apoptosis among MOLT-4 and Reh cells in a time- and dose-dependent manner. Moreover, LBH589 is more potent in MOLT-4 than in Reh cells. LBH589 markedly prevents the growth of both MOLT-4 and Reh cells in a dose-dependent manner at 48 hours. LBH589 treatment causes a 2- to 3-fold increase in the number of cells in the G2/M phase of the cell cycle compared with the control cells. LBH589 is associated with induction of histone H3K9 and histone H4K8 acetylation as well as decreasing levels of c-Myc expression in a dose-dependent manner. LBH589 treatment also increases the levels of p21 expression. LBH589 treatment also decreases the levels of c-Myc after an initial increase at the lowest dose (10 nM) in Reh cells. In addition, LBH589 gives rise to substantial increases in mRNA levels of proapoptosis and DNA repair genes. LBH589 induces increased levels of acetylated histone H3 and H4 at the GADD45G promoter. ^[1] Besides, LBH589 inhibits growth of non small cell lung cancer cell lines (such as human H1299, L55 and A549 with IC50 of 5 nM, 11 nM and 30 nM, respectively), mesothelioma (such as human OK-6 and Ok-5 with IC50 of 5 nM and 7 nM, respectively) and small cell lung cancer cell lines (such as human RG-1 and LD-T with IC50 of 4 nM and 5 nM, respectively). ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HT29	NWn5UIVRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4ToV\|AuOTBizszN	NFrjTpUxNTRiZB?=		M2eySolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MoH1NlY4ODJ5OES=
HepG2	M4nRO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm[4NE0yOCEQvF2=	NH7uTHoxNTRiZB?=		M{nTT4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MkjONlY4ODJ5OES=
HT29	NYnLZm56TnWwY4Tpc44hSXO\|YYm=	MlHqOVDDqG6P	M3nzeFI1NTd{IHi=		MXrpcoR2[2WmIHHjeIl3[XSrb36gc4Yh[2G\|cHHz[UA{KGGodHXyJFQ5yqCqwrC=	M4XQUVI3PzB{N{i0
HepG2	MkTESpVv[3Srb36gRZN{[Xl?	NWTMNYJZPTEEoH7N	M4HMO\|I1NTd{IHi=		Mk[0bY5lfWOnZDDhZ5RqfmG2aX;uJI9nKGOjc4Dhd4UhOyCjZoTldkAzPMLiaNMg	MmLjNlY4ODJ5OES=
HCC827	MlfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWTwXnpbPS95LkWvNVAhdk1?	NGDmOXU4OsLiaB?=	M{DIemROW09?	MnTR[Y5p[W6lZYOgeIhmKGGwdHnwdo9tcW[ncnH0bZZmKGWoZnXjeEBw\iCncnzveIlvcWJ?	MV2yOlY4PTR6NB?=
A549	MlzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXXCO5VsOTBxMUWvNlAhdk1?	M4PFOVczyqCq	M2jWPWROW09?	Ml7G[Y5p[W6lZYOgeIhmKGGwdHnwdo9tcW[ncnH0bZZmKGWoZnXjeEBw\iCncnzveIlvcWJ?	MWmyOlY4PTR6NB?=
NCI-H460	NFGwbHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXixNE8zOC9\|MDDuUS=>	NHfVT\|c4OsLiaB?=	M4nwUmROW09?	NYj1dmZj\W6qYX7j[ZMhfGinIHHueIlxem:uaX\ldoF1cX[nIHXm[oVkfCCxZjDldoxwfGmwaXK=	M4XyNlI3Pjd3NEi0
J89GFP	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MW\EUXNQyqB?	NGLMdlhGSzVyPUS5Mlg2KMLzIEGyMlY2KG6P	NW\5Oo4yOjZ3NkO1Olg>
THP89GFP	M{Pybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Ml;xSG1UV8Li	Mk\HSWM2OD1zOT6zOEDDuSB4LkSzJI5O	M3rCV\|I3PTZ\|NU[4
SK-NEP-1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkDFNE4xOeLCk{GwMlAh\|ryP	NITnZ5gzPCCq	M3zxNGROW00EoB?=	MmPZTWM2OD15Nj6zOEBvVQ>?	NHr5WGozPjF5NkKxPS=>
G401	NVr2SpRJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXSwMlAy6oDVMUCuNEDPxE1?	NEjzcXQzPCCq	NEXyXIRFVVORwrC=	MXnJR\|UxRTF2Mz6wNkBvVQ>?	NIPqT\|gzPjF5NkKxPS=>
SK-NEP-1	MXjD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MlvoOVAhdk1?	MYOx5qCUPCCm	MmrlSG1UV8Li	MYHy[YR2[2W\|IHPlcIwhe3W{dnn2ZYwhcW5iYTD0bY1mKGSncHXu[IVvfCCvYX7u[ZI>	MlPtNlYyPzZ{MUm=
G401	NEPJbpZE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MXu1NEBvVQ>?	MXux5qCUPCCm	MYDEUXNQyqB?	M3[xR5Jm\HWlZYOgZ4VtdCC\|dYL2bZZidCCrbjDhJJRqdWViZHXw[Y5l\W62IH3hco5meg>?	MXWyOlE4PjJzOR?=
SK-NEP-1	NVjUcpIzSXCxcITvd4l{KEG\|c3H5	M3PEflUxNzFyMDDuUS=>	M{PFV\|I1KGh?	MnjZSG1UV8Li	Ml;abY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	M17RSFI3OTd4MkG5
G401	M2XQTGFxd3C2b4Ppd{BCe3OjeR?=	Mon2OVAwOTByIH7N	NFXUXm4zPCCq	NVrJUHJkTE2VT9Mg	MWDpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	M3[zZVI3OTd4MkG5
SK-NEP-1	M{PNOWZ2dmO2aX;uJGF{e2G7	MnnUOVAwOTByIH7N	NYr1R5NCOjRiaB?=	NID4dldFVVORwrC=	NFqwT5p{cG:5czD0bIUhcW6mdXP0bY9vKG:oIFTORUBnemGpbXXueIF1cW:w	NVLC[oNFOjZzN{[yNVk>
G401	MV3GeY5kfGmxbjDBd5NigQ>?	MVi1NE8yODBibl2=	M1fPRVI1KGh?	MmTrSG1UV8Li	MoXUd4hwf3NidHjlJIlv\HWldHnvckBw\iCGTlGg[pJi\22nboTheIlwdg>?	MkXNNlYyPzZ{MUm=
SK-NEP-1	NXTHdYpYTnWwY4Tpc44hSXO\|YYm=	MkC2OVAwOTByIH7N	MmnKNlQhcA>?	NI\aR2tFVVORwrC=	NIHVTJBqdmS3Y3XzJINmdGxiY4njcIUh\Gm\|b4Lk[ZLDqA>?	Ml33NlYyPzZ{MUm=
G401	NXzkRYY2TnWwY4Tpc44hSXO\|YYm=	NGHHXVA2OC9zMECgcm0>	MmWzNlQhcA>?	NVfSOnRHTE2VT9Mg	NGXmRVFqdmS3Y3XzJINmdGxiY4njcIUh\Gm\|b4Lk[ZLDqA>?	MlrONlYyPzZ{MUm=
RPMI 8226	MUHD[YxtKFO3co\peoFtKEG\|c3H5	NUXjfmk4Oi92L{[gcm0>	Ml:1OFjjiImq		MVXpcoR2[2W\|IHGgd4lodmmoaXPhcpQh\GWlcnXhd4UhcW5idHjlJINmdGxiZ4Lve5Rp	NYKzVlhROjZyMECyPVI>
OPM2	NGL0bIlE\WyuIGP1dpZqfmGuIFHzd4F6	Mm\PNk81NzZibl2=	M{DsUFQ56oDLaB?=		MXzpcoR2[2W\|IHGgd4lodmmoaXPhcpQh\GWlcnXhd4UhcW5idHjlJINmdGxiZ4Lve5Rp	M2\xV\|I3ODByMkmy
U266	M4TlcGNmdGxiU4Xyeol3[WxiQYPzZZk>	MoKyNk81NzZibl2=	NWnBN3BOPDkkgJno		Mln1bY5lfWOnczDhJJNq\26rZnnjZY51KGSnY4LlZZNmKGmwIITo[UBk\WyuIHfyc5d1cA>?	M2\KNlI3ODByMkmy
H929	NWHLfoVzS2WubDDTeZJ3cX[jbDDBd5NigQ>?	MnTsNk81NzZibl2=	NHHDZ3I1QOLCiXi=		MX;pcoR2[2W\|IHGgd4lodmmoaXPhcpQh\GWlcnXhd4UhcW5idHjlJINmdGxiZ4Lve5Rp	MVuyOlAxODJ7Mh?=
RPMI 8226	NYPYd45NSXCxcITvd4l{KEG\|c3H5	NXGxZ2RzPOLCiX7N	MXWyOE81QCCq		NXL0OVNFcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKHSrbXWt[IVx\W6mZX70JI1idm6nch?=	NWnvPYpYOjZyMECyPVI>
HCC827	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGPvfVcyOCCwTR?=	NWfSXYRWPDhiaB?=	NXHjenUzTE2VTx?=	NVTuO5Qy\W6qYX7j[ZMh[2m\|cHzheIlvKHOnboPpeIl3cXS7wrC=	NIDudJczPTl2NE[xOy=>
NCI-H23	Mk\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlTwNVAhdk1?	NXKxd\|g6PDhiaB?=	M{DnbmROW09?	NYO4enFU\W6qYX7j[ZMh[2m\|cHzheIlvKHOnboPpeIl3cXS7wrC=	MXeyOVk1PDZzNx?=
AML3	NInyXlNHfW6ldHnvckBCe3OjeR?=	MVqwMVEh\|ryP	M3;2R\|I1yqCq		MYrpcoR2[2W\|IFTORUBnemGpbXXueIF1cW:wwrDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NH\qUpUzPTZzMkm0NS=>
ML-1	NHy5OY9HfW6ldHnvckBCe3OjeR?=	NVLUSG1mOC1zIN88US=>	NGnpO5EzPMLiaB?=		NG\IXHVqdmS3Y3XzJGRPSSCocnHncYVvfGG2aX;uxsBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	MViyOVYyOjl2MR?=
RPMI-8226vr10	MVXGeY5kfGmxbjDBd5NigQ>?	NYHJWnJXOC1zIN88US=>	MnX6NlTDqGh?		M3fWcolv\HWlZYOgSG5CKG[{YXft[Y51[XSrb39CpIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	MUOyOVYyOjl2MR?=
ML-1	M4LxTGZ2dmO2aX;uJGF{e2G7	NWO2cnVoOSEQvF2=	NV7ReVlIOjUEoHi=		NX32T3FTcW6lcnXhd4V{KGOjc4Dhd4UuOyCjY4Tpeol1gSB2LX\vcIQ>	NYDVXJV5OjV4MUK5OFE>
RPMI-8226vr10	M2rn[GZ2dmO2aX;uJGF{e2G7	M2DmSlEh\|ryP	M3POTlI1yqCq		NWDvVGZ6cW6lcnXhd4V{KGOjc4Dhd4UuOyCjY4Tpeol1gSB{LkWt[o9t\A>?	MVqyOVYyOjl2MR?=
SK-N-BE (2)	M1rHVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUKyOQKBkWh?		MlzTTWM2OD1zMESuNQKBkcLz4pEJO{45KG6P	MWiyOVMxQDlzNh?=
SK-N-BE (2), PAN MK	NIrUcYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MX6yOQKBkWh?		M{PlOmlEPTB;MUC0MlDjiIoEsfMAjVcvQCCwTR?=	MX[yOVMxQDlzNh?=
SK-N-BE (2), MK PAN	M4nXUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Ml;MNlTjiImq		NF\Cb25KSzVyPUO4Nk4x6oDLwsJihKk1Oy5{IH7N	MnfrNlU{ODh7MU[=
SK-N-AS	NI\TdIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NI\lcWUzPOLCiXi=		NH\BXHJKSzVyPUO3MlHjiIoEsfMAjVIvPCCwTR?=	NVnmc\|hJOjV\|MEi5NVY>
SK-N-DZ	NG\YVJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWmyOQKBkWh?		M2fvNmlEPTB;MUeuNgKBkcLz4pEJNE41KG6P	MnXQNlU{ODh7MU[=
Caki-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWn0bpU6OTBxMkWvOVAhdk1?	Mn3oOFghcA>?		NGjl[\|RqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC\|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK=	NYfmflBuOjV{N{mxPVE>
ACHN	M3nh[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3fNUlExNzJ3L{WwJI5O	M{jkd\|Q5KGh?		MlvhbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhicnn0c45ifmm{	M3zydVI2Ojd7MUmx
769-P	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M37RXVExNzJ3L{WwJI5O	MVu0PEBp		MmL5bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhicnn0c45ifmm{	MWeyOVI4QTF7MR?=
786-O	Ml3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{XHO\|ExNzJ3L{WwJI5O	NVHs[ZFCPDhiaB?=		NEnaXXZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC\|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK=	MUSyOVI4QTF7MR?=
Caki-1	NYLoZpZ6SXCxcITvd4l{KEG\|c3H5	M2XifFUxKG6P	MXG0PEBp		MlrDbY5lfWOnczDj[YxtKGGyb4D0c5NqeyClb33ibY5m\CC{aYTvcoF3cXJ?	M4\Cd\|I2Ojd7MUmx
ACHN	MV7BdI9xfG:\|aYOgRZN{[Xl?	M4LiVVUxKG6P	NH7WZ5Q1QCCq		M2rpc4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNiY3;tZolv\WRicnn0c45ifmm{	Ml;NNlUzPzlzOUG=
769-P	MVnBdI9xfG:\|aYOgRZN{[Xl?	MXW1NEBvVQ>?	MVS0PEBp		NV3CSI5wcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDjc41jcW6nZDDybZRwdmG4aYK=	NFS3UnczPTJ5OUG5NS=>
786-O	MYPBdI9xfG:\|aYOgRZN{[Xl?	M2nGV\|UxKG6P	NYq5c2J7PDhiaB?=		MojDbY5lfWOnczDj[YxtKGGyb4D0c5NqeyClb33ibY5m\CC{aYTvcoF3cXJ?	MmHnNlUzPzlzOUG=
Caki-1	M2jP[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWHqflc2OjVxNUCgcm0>	M3nQcFQ5KGh?	NX3wXVVkTE2VTx?=	NHS1UHdqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC\|eX7ldodqe3SrY3HscJkhf2m2aDDic5J1\XqxbXni	M1K1ZVI2OTd4M{W0
ACHN	NIKzUWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1\6U\|I2NzVyIH7N	MlvNOFghcA>?	NULwXphnTE2VTx?=	NULPXFc3cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJic4nu[ZJocXO2aXPhcIx6KHerdHigZo9zfGW8b33pZi=>	M{K0WFI2OTd4M{W0
769-P	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{m1[lI2NzVyIH7N	NVfxWW13PDhiaB?=	M1LwW2ROW09?	MnLObY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhiYn;yeIV7d22rYh?=	NYOwNXpqOjVzN{[zOVQ>
Caki-1	NXHBem9GS2:ub375JGZwem2jdHnvckBCe3OjeR?=	NUT6XoV2PTBibl2=	M3Sw[\|cuOTRiZB?=	MoXUSG1UVw>?	MVTzeZBxemW\|c3XkJINwdG:weTDmc5Ju[XSrb36gd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJJdqfGhiYn;yeIV7d22rYjFCpC=>	MUKyOVE4PjN3NB?=
ACHN	Mn;NR49td267IF\vdo1ifGmxbjDBd5NigQ>?	NFzoZWM2OCCwTR?=	MYm3MVE1KGR?	NWS0bmNkTE2VTx?=	MkG1d5VxeHKnc4Pl[EBkd2yxbomg[o9zdWG2aX;uJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEB4cXSqIHLvdpRmgm:vaXKgxsA>	NUTCXpVvOjVzN{[zOVQ>
769-P	NEjxV\|VEd2yxbomgSo9zdWG2aX;uJGF{e2G7	MVK1NEBvVQ>?	NGTkeFU4NTF2IHS=	NFzIRZFFVVOR	M1u4NpN2eHC{ZYPz[YQh[2:ub375JIZwem2jdHnvckB{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIghf2m2aDDic5J1\XqxbXniJOKh	MV[yOVE4PjN3NB?=
Caki-1	M4m5R2Fxd3C2b4Ppd{BCe3OjeR?=	M3uxW\|UxKG6P	M4GxVVQ5KGh?	MUnEUXNQ	MmLObY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	NEnmbGszPTF5NkO1OC=>
ACHN	MlvhRZBweHSxc3nzJGF{e2G7	MkPjOVAhdk1?	NHe1UXM1QCCq	MlrvSG1UVw>?	MXLpcoR2[2W\|IHPlcIwh[XCxcITvd4l{	NV;DbZpHOjVzN{[zOVQ>
769-P	NFG5eJVCeG:ydH;zbZMhSXO\|YYm=	NX7HOopkPTBibl2=	NWqzbYVPPDhiaB?=	MlPHSG1UVw>?	NVvyPGtJcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	NGjBW\|czPTF5NkO1OC=>
MDA-MB-231	M{jxZm1wenCqb3zv[4lk[WxiQ4L5d5RidCCYaX;s[ZQhMEOYKTDBd5NigQ>?	M2XHWFExyqCwTR?=	NG[4R5E{yqCm	MWTEUXNQ	NVH6OZF{[Wy2ZYLzJINmdGxibX;ydIhwdG:pedMg	M3XPflI1QDFyNEm3
BT-549	MVzNc5JxcG:ub3fpZ4FtKEO{eYP0ZYwhXmmxbHX0JEhEXiliQYPzZZk>	M4nZNlExyqCwTR?=	NWnHUFgxO8LiZB?=	NWTrcXZiTE2VTx?=	NU\KZnc3[Wy2ZYLzJINmdGxibX;ydIhwdG:pedMg	NHr0VXozPDhzMES5Oy=>
MCF-7	NVXjUXdPVW:{cHjvcI9ocWOjbDDDdpl{fGGuIG\pc4xmfCBqQ2[pJGF{e2G7	MkK0NVDDqG6P	MVuzxsBl	M2fHNmROW09?	Mmq1ZYx1\XK\|IHPlcIwhdW:{cHjvcI9ogcLi	MXyyOFgyODR7Nx?=
MCF-7	NET5VlNHfW6ldHnvckBCe3OjeR?=	NYG4SZRlPS13MDDuUS=>	MlLTNlQhcA>?	MkL6SG1UVw>?	NECyfW1z\WS3Y3XkJJRp\SCuZY\lcEBw\iCneIDy[ZN{cW:wIH;mJGVT\|rFuIGDSJIFv\CCIb4jBNeKh	MkXTNlQ{PjZ2MEe=
CTS	M{myXmFxd3C2b4Ppd{BCe3OjeR?=	NG\KUpUx6oDVNECgcm3DqA>?	NGrXVWM1QCCq		MluxbY5lfWOnczDhdI9xfG:\|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NFu5U\|czPDJ2NESyPS=>
OCI-AML3	MUXBdI9xfG:\|aYOgRZN{[Xl?	M2nOc\|DjiJN2MDDuUeKh	MVW0PEBp		MWPpcoR2[2W\|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NXrhW2UyOjR{NES0Nlk>
U937	Mn;lRZBweHSxc3nzJGF{e2G7	NW\NZYx6OOLCk{SwJI5OyqB?	M4Swd\|Q5KGh?		MV7pcoR2[2W\|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NITRfFUzPDJ2NESyPS=>
PC3	NUHK[\|hISXCxcITvd4l{KEG\|c3H5	M3rQc\|AuOTByIH7N	MYmyOE81QCCq		M3;XdIlv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	MUSyOFE3OzJ\|MB?=
PC3-AR	NWTQ[nd6SXCxcITvd4l{KEG\|c3H5	MV2wMVExOCCwTR?=	M2DH[lI1NzR6IHi=		NH3aRZdqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MWCyOFE3OzJ\|MB?=
PC3	NWXTVnpmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1jWXlAuOTByIH7N	MX6yOE81QCCq		MXPpcoR2[2W\|IHHjZ5VufWyjdHnvckBw\iC\|dXLHNUBxd3C3bHH0bY9v	M2\pTlI1OTZ\|MkOw
PC3-AR	NIDwOJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXuwMVExOCCwTR?=	NIm5fGYzPC92ODDo		MnWybY5lfWOnczDj[YxtKGO7Y3zlJIFzemW\|dDDpckB1cGViR{LNJJBp[XOn	M13aPFI1OTZ\|MkOw
PC3	M1zGbmZ2dmO2aX;uJGF{e2G7	MViwMVExOCCwTR?=	NIjKRoYzPCCq		NFXQbGp{fXCycnXzd4V{KGW6cILld5Nqd25ib3[gZYN1cX[jdHXkJGFVVSxiQXv0JIFv\CCHcnuxM\|IheHKxdHXpci=>	NUewdY1WOjRzNkOyN\|A>
PC3-AR	NVzkWZI3TnWwY4Tpc44hSXO\|YYm=	MWiwMVExOCCwTR?=	M2[yOVI1KGh?		MnrZd5VxeHKnc4Pld{BmgHC{ZYPzbY9vKG:oIHHjeIl3[XSnZDDBWG0tKEGtdDDhcoQhTXKtMT:yJJBzd3SnaX6=	NXnNVGxXOjRzNkOyN\|A>
OS-RC-2	M1HPOGNmdGxiVnnhZoltcXS7IFHzd4F6	NHXnWJAxNTFyMECgcm0>	MVSyOE81QC95MjDo	M1\Ob2ROW09?	MWXk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NGTtb5AzPDF2NEezOy=>
OS-RC-2	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUHRPINCPTBibl2=	NIi3Voc1QCCq	M1nPN2ROW09?	M3T1OIlv\HWlZYOgS\|IwVSCjcoLld5Q>	M3X5eFI1OTR2N{O3
OS-RC-2	NUjTNFFWSXCxcITvd4l{KEG\|c3H5	MoO4OVAhdk1?	NYfhPXNUPDhiaB?=	NU[4TXF2TE2VTx?=	NE\JSWVqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	MofhNlQyPDR5M{e=
SK-N-AS	NIPjPWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1vwblDjiJN6MDDuUS=>	MoWyOFghcA>?		MojiTWM2OD1{Nz60JI5O	MXeyOFA6QDd7OR?=
SK-N-DZ	NVP6ZmQxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFi0TIgx6oDVOECgcm0>	NVzob\|N[PDhiaB?=		NXvKZ\|JQUUN3ME2yNU46KG6P	MXyyOFA6QDd7OR?=
SK-N-SH	NHnHVpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2fLZ\|DjiJN6MDDuUS=>	NWjqem5DPDhiaB?=		M{\xZ2lEPTB;N{KuN{BvVQ>?	MorYNlQxQTh5OUm=
SK-N-BE	MkfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVOw5qCUQDBibl2=	NH\ROo81QCCq		MnPVTWM2OD15NT60JI5O	NGPBcYszPDB7OEe5PS=>
SK-N-AS	M1y1UGFxd3C2b4Ppd{BCe3OjeR?=	MmHNNQKBmzhyIH7N	Mo\ZOFghcA>?		M3fiT5BwfGWwdHz5JIlv\HWlZXSgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQh\mG\|aHnvci=>	NWDhNHM4OjRyOUi3PVk>
SK-N-DZ	NVrUdZdLSXCxcITvd4l{KEG\|c3H5	NYrG[W1nOOLCk{iwJI5O	M1zLdFQ5KGh?		NYjEU5RteG:2ZX70cJkhcW6mdXPl[EBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCoYYPobY9v	NGLMboIzPDB7OEe5PS=>
SK-N-SH	NY\FTotbSXCxcITvd4l{KEG\|c3H5	MknKNQKBmzRyIH7N	MWG0PEBp		MkfQdI91\W62bImgbY5lfWOnZDDhdI9xfG:\|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBn[XOqaX;u	M1LzTlI1ODl6N{m5
SK-N-BE	NXLJbINFSXCxcITvd4l{KEG\|c3H5	M3vmRlDjiJN2MDDuUS=>	MUC0PEBp		M3j3WZBwfGWwdHz5JIlv\HWlZXSgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQh\mG\|aHnvci=>	Mn\aNlQxQTh5OUm=
SK-N-AS	M1\nOWZ2dmO2aX;uJGF{e2G7	MVuw5qCUQDBibl2=	M{DkVFQ5KGh?		MkXqbY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHPs[YF3[WenIH;mJINie3Cjc3WgN{BidmRiUFHSVC=>	MnnmNlQxQTh5OUm=
SK-N-DZ	MVHGeY5kfGmxbjDBd5NigQ>?	NUjyNFhUOOLCk{iwJI5O	MkiyOFghcA>?		NUXNdlc2cW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JINt\WG4YXflJI9nKGOjc4Dhd4UhOyCjbnSgVGFTWA>?	NIT2TXMzPDB7OEe5PS=>
SK-N-SH	NULtXYhQTnWwY4Tpc44hSXO\|YYm=	MoTQNQKBmzRyIH7N	MVq0PEBp		NV3zWFY4cW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JINt\WG4YXflJI9nKGOjc4Dhd4UhOyCjbnSgVGFTWA>?	NFGyN5EzPDB7OEe5PS=>
SK-N-BE	NWT1Vmd4TnWwY4Tpc44hSXO\|YYm=	MY[w5qCUPDBibl2=	MUG0PEBp		MXXpcoR2[2W\|IHGg[I9{\S2mZYDlcoRmdnRiY3zlZZZi\2Vib3[gZ4F{eGG\|ZTCzJIFv\CCSQWLQ	M1f4UFI1ODl6N{m5
HCC-LM3	MmPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX:xMVExODBibl2=	NGPHPHkzPC92OD:3NkBp	M4fvXGROW09?	Mn7nbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	M3rTN\|I1ODl\|OUW2
HepG2	Mn3YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlzPNU0yODByIH7N	MkHzNlQwPDhxN{KgbC=>	NEHjRnpFVVOR	Ml\QbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	M1TYT\|I1ODl\|OUW2
SMMC-7721	NFPhO2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2juXVEuOTByMDDuUS=>	NV7Yb5VnOjRxNEivO\|IhcA>?	NITBW\|RFVVOR	MmC4bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	M33IU\|I1ODl\|OUW2
HCC-LM3	MVfBdI9xfG:\|aYOgRZN{[Xl?	MVi1NEBvVQ>?	NIi0bYs1QCCq	MnXFSG1UVw>?	MoL4bY5lfWOnczDj[YxtKGGyb4D0c5NqeyC\|aXfubYZq[2GwdHz5JIlvKGFiY3HzdIF{\S2mZYDlcoRmdnRibXHucoVzKGK7IHPs[YF3[WenIH;mJINie3Cjc3XzJFMtKDhiYX7kJFk>	NIS4W3gzPDB7M{m1Oi=>
HepG2	M2OyPGFxd3C2b4Ppd{BCe3OjeR?=	NYXBZ3hiPTBibl2=	MVG0PEBp	NGTnS5VFVVOR	M3SxSYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfUBqdiCjIHPhd5Bie2VvZHXw[Y5l\W62IH3hco5meiCkeTDjcIVifmGpZTDv[kBk[XOyYYPld{A{NCB6IHHu[EA6	M{jVflI1ODl\|OUW2
SMMC-7721	M3zab2Fxd3C2b4Ppd{BCe3OjeR?=	NIe2OGc2OCCwTR?=	NVXQc3U1PDhiaB?=	M4DPc2ROW09?	M1XVUIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfUBqdiCjIHPhd5Bie2VvZHXw[Y5l\W62IH3hco5meiCkeTDjcIVifmGpZTDv[kBk[XOyYYPld{A{NCB6IHHu[EA6	M2jYWFI1ODl\|OUW2
HCC-LM3	MWnGeY5kfGmxbjDBd5NigQ>?	MkfzOVAwOTByIH7N	MXqyOEBp	NXrFVmd7TE2VTx?=	MVnk[YNz\WG\|ZYOgeIhmKGyndnXsd{Bw\iCyLWPURXQ{KGGwZDDwMWFsfMLi	NYjD[nZFOjRyOUO5OVY>
HepG2	MW\GeY5kfGmxbjDBd5NigQ>?	MXu1NE8yODBibl2=	NWS0cnJnOjRiaB?=	MVrEUXNQ	NUj6SplM\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gdE1UXEGWMzDhcoQheC2Da4VCpC=>	MYiyOFA6Ozl3Nh?=
SMMC-7721	MX3GeY5kfGmxbjDBd5NigQ>?	MYi1NE8yODBibl2=	M4jKbFI1KGh?	MmLxSG1UVw>?	NWXHdlYy\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gdE1UXEGWMzDhcoQheC2Da4VCpC=>	MkHrNlQxQTN7NU[=
HCC-LM3	MnywSpVv[3Srb36gRZN{[Xl?	MWK1NE8yODBibl2=	M{mzRlI1KGh?	M2fnZWROW09?	NYfD[nNs\G:5boLl[5Vt[XSnczDCZ4wugExiZYjwdoV{e2mxbh?=	NHLvenIzPDB7M{m1Oi=>
HepG2	MWjGeY5kfGmxbjDBd5NigQ>?	NIrYOYY2OC9zMECgcm0>	MmrZNlQhcA>?	M13GVWROW09?	MYXkc5dvemWpdXzheIV{KEKlbD34UEBmgHC{ZYPzbY9v	MXWyOFA6Ozl3Nh?=
SMMC-7721	NYfGTWpuTnWwY4Tpc44hSXO\|YYm=	M{TGT\|UxNzFyMDDuUS=>	M1;qWVI1KGh?	NGC5NW9FVVOR	MoKy[I94dnKnZ4XsZZRmeyCEY3ytfGwh\XiycnXzd4lwdg>?	MWiyOFA6Ozl3Nh?=
FaDu	Mli1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnrXNVAx6oDHbl2=	MX64M\|ExNzF{IHi=		MXvkbZNxdGG7ZXSgZUB{cWewaX\pZ4FvfCCjbnSgdJJwdG:wZ3XkJGczN01iYYLy[ZN1KGG2IEigZY5lKDF{4pEFbEBxd3O2IILlcIVie2V?	MnXnNlQxOjZ2OEK=
FaDu	Ml3qSpVv[3Srb36gRZN{[Xl?	Ml;FNVAx6oDHbl2=	MnvjNk81NzhxMUKgbC=>		M4\CR4lv\HWlZXSgdFIyX2GoMT;DbZAyyqCneIDy[ZN{cW:w	MonaNlQxOjZ2OEK=
PC-3	NFe0TYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPEPYtMOC1zMDFOwG0>	M3fGdVI1NzR6L{eyJIg>		MXzpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MoHONlM6QTF{MU[=
LNCaP	NEfCeJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn[2NE02KM7:TR?=	NFj1SJAzPC92OD:3NkBp		NIrkS5BqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NYjFWFJIOjN7OUGyNVY>
RWPE-1	NULXbpd2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4TNU\|AuOjBizszN	MXSyOE81QC95MjDo		NHryUYRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NUfPb3FlOjN7OUGyNVY>
Capan-1	NUDZe5lTTnWwY4Tpc44hSXO\|YYm=	M3u2[VI2NzVyL{GwNEBvVQ>?	M13u[VgwOjRxNEigbC=>	MXnEUXNQ	MYjkc5dvemWpdXzheIVlKFKxbjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36gZY5lKGSxd37zeJJm[W1ic3nncoFtcW6p	MViyN\|kzOjh6Nh?=
L3.6pl	MorsSpVv[3Srb36gRZN{[Xl?	MV:yOU82OC9zMECgcm0>	NH7QRYw5NzJ2L{S4JIg>	M1HWdGROW09?	MVnkc5dvemWpdXzheIVlKFKxbjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36gZY5lKGSxd37zeJJm[W1ic3nncoFtcW6p	M3q0fFI{QTJ{OEi2
CFPAC-1	MVjGeY5kfGmxbjDBd5NigQ>?	NGC3fpgzPS93MD:xNFAhdk1?	M37ydVgwOjRxNEigbC=>	MYTEUXNQ	MX;kc5dvemWpdXzheIVlKFKxbjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36gZY5lKGSxd37zeJJm[W1ic3nncoFtcW6p	MXKyN\|kzOjh6Nh?=
Capan-1	NUXBeIpVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG[zNpAzPS93MD:xNFAhdk1?	M4noeVQ5KGh?	NGjnSVVFVVOR	MmrodoVlfWOnczDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	M4\TNlI{QTJ{OEi2
L3.6pl	M3rxOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYOwNWpbOjVxNUCvNVAxKG6P	MojrOFghcA>?	NYj2c2RMTE2VTx?=	Mnu1doVlfWOnczDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	NE\VNoozOzl{Mki4Oi=>
CFPAC-1	MoKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPR[nVHOjVxNUCvNVAxKG6P	MnnJOFghcA>?	NXfhNJJsTE2VTx?=	NHrvblJz\WS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MVGyN\|kzOjh6Nh?=
Capan-1	MmLvRZBweHSxc3nzJGF{e2G7	MoeyNlUwPTBxMUCwJI5O	NX;IeXN3PDhiaB?=	M3\1W2ROW09?	MWnpcoR2[2W\|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	M4q4ZlI{QTJ{OEi2
L3.6pl	MlXsRZBweHSxc3nzJGF{e2G7	MXGyOU82OC9zMECgcm0>	NF64VlM1QCCq	NIX0XWZFVVOR	NVXPNoFrcW6mdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	NH\Mco0zOzl{Mki4Oi=>
CFPAC-1	MVnBdI9xfG:\|aYOgRZN{[Xl?	MUWyOU82OC9zMECgcm0>	MW[0PEBp	MX3EUXNQ	MoTxbY5lfWOnczDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	MlK1NlM6OjJ6OE[=
HN22	NFzCb5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3frSVAuOjBibl2=	M37MVVI1NzR6IHi=	M{nWcWROW09?	NH3YdGRqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUuKGGwZDDkc5NmNSCmZYDlcoRmdnRibXHucoVz	M1jvU\|I{QDd5MkO1
HSC4	NHHkdYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX6wMVIxKG6P	MmHPNlQwPDhiaB?=	M37I[2ROW09?	NYjIWINxcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S1iZHXw[Y5l\W62IH3hco5meg>?	MXyyN\|g4PzJ\|NR?=
HN22	MUHBdI9xfG:\|aYOgRZN{[Xl?	MoG0NE0zOCCwTR?=	NWG3V3BUPDhiaB?=	NUnndJFqTE2VTx?=	M4XmTYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	NXziUFhSOjN6N{eyN\|U>
HSC4	NYrKSlNCSXCxcITvd4l{KEG\|c3H5	NWWwW2M1OC1{MDDuUS=>	MY[0PEBp	MnrwSG1UVw>?	MV\pcoR2[2W\|IHPlcIwh[XCxcITvd4l{	MVWyN\|g4PzJ\|NR?=
HN22	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH;QfGYxNTJyIH7N	NGC0fVg1QCCq	NVfISmg2TE2VTx?=	M{LEWIlv\HWlZYOgS\|EheGijc3WgZ4VtdCCleXPs[UBienKnc4VCpC=>	NFHXcmgzOzh5N{KzOS=>
HSC4	NF3Qc4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYCwMVIxKG6P	MW[0PEBp	M4O0NGROW09?	MVLpcoR2[2W\|IFexJJBp[XOnIHPlcIwh[3mlbHWgZZJz\XO2wrC=	NYDldIJlOjN6N{eyN\|U>
HN22	NUjrU4FPTnWwY4Tpc44hSXO\|YYm=	NWjQc5l4OC1{MDDuUS=>	M2CxdlQ5KGh?	NYnCO5QxTE2VTx?=	NXi5WpEze3WycILld5NmeyCVcEGg[ZhxemW\|c3nvcuKh	MXuyN\|g4PzJ\|NR?=
HSC4	MmXqSpVv[3Srb36gRZN{[Xl?	NYPKb4s4OC1{MDDuUS=>	MljROFghcA>?	NXHOb\|NqTE2VTx?=	NXWzSnhDe3WycILld5NmeyCVcEGg[ZhxemW\|c3nvcuKh	NHjsZ3IzOzh5N{KzOS=>
Cal62	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX6yPGIyUUN3ME2zN{DDuSB2IH7N	MkP5NlM5OjRyNkS=
Hth7	M{XLU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXOxW4JoUUN3ME2xOUDDuSB{IH7N	M2qxOVI{QDJ2ME[0
Hth83	NXnQT3o1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4HSXGlEPTB;M{SgxtEhPSCwTR?=	NWjF[pJSOjN6MkSwOlQ>
C643	MlLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mo\4TWM2OD15MTFCtUAyOCCwTR?=	MnnnNlM5OjRyNkS=
SW1736	Mn\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYrtdo56UUN3ME2zOUDDuSB6IH7N	MlS3NlM5OjRyNkS=
T241	NY[4W2ZGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2rpVWlEPTB;NkWgxtEhPyCwTR?=	MoX0NlM5OjRyNkS=
T351	MoHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVvJR\|UxRTVyINMxJFExKG6P	M1nkbVI{QDJ2ME[0
BHP2-7	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1zCWWlEPTB;M{egxtEhPiCwTR?=	MWmyN\|gzPDB4NB?=
T238	MmnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml3xTWM2OD1zLEWwNEDDuSB{MECgcm0>	M{G5dlI{QDJ2ME[0
HCT8	M2q2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWPZS2V1PzJiaB?=	M{K4WmROW09?	Mn;tTWM2OD1zMj655qCKyrIkgJmxMlkhdk1?	MlLCNlMzQTl\|OEi=
H630	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{PlPVczKGh?	NGXHeIJFVVOR	M3\ZOGlEPTB;MUKuOQKBkcLz4pEJN{4yKG6P	NGr1[oYzOzJ7OUO4PC=>
cH630 5-FU-res	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXm5Zmx3PzJiaB?=	MWrEUXNQ	MnnQTWM2OD1zNT615qCKyrIkgJmxMlIhdk1?	MV[yN\|I6QTN6OB?=
HCT116	MonoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MYO3NkBp	NEjBXYNFVVOR	MUHJR\|UxRTFyLkhihKnDueLCiUKuNkBvVQ>?	M3vBXFI{Ojl7M{i4
HCT116 p53−/−	M{PrOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MWO3NkBp	NXTJOoVGTE2VTx?=	MmTGTWM2OD16LkdihKnDueLCiUGuO{BvVQ>?	MYWyN\|I6QTN6OB?=
dHCT116 p21−/−	M1mx[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{ftbFczKGh?	M{fyW2ROW09?	NHmyNItKSzVyPUWuPgKBkcLz4pEJNU4{KG6P	MWmyN\|I6QTN6OB?=
HT29	MlLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnvPO\|IhcA>?	MV;EUXNQ	MYTJR\|UxRTF4LkRihKnDueLCiUKuN{BvVQ>?	MVKyN\|I6QTN6OB?=
LoVo	NFiwVmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXi3NkBp	MVjEUXNQ	NFTFTHBKSzVyPUWuNgKBkcLz4pEJNE43KG6P	M1TaNlI{Ojl7M{i4
RKO	NVrCWFRCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUHCNYRNPzJiaB?=	M3v2NGROW09?	NW\MbYZKUUN3ME23MlnjiIoEsfMAjVIvOiCwTR?=	M3TvWFI{Ojl7M{i4
SW480	M1:wN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2\U[FczKGh?	NGjne2tFVVOR	MUnJR\|UxRTF5LkZihKnDueLCiUCuPEBvVQ>?	NIPybVkzOzJ7OUO4PC=>
eSW620	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MYK3NkBp	NGDXTVlFVVOR	MVHJR\|UxRTlwMfMAjeKy6oDLMj6xJI5O	NXXSRoFpOjN{OUmzPFg>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	DNMT1 / EZH2; PubMed: 19279403 Cancer Biol Ther Western blot of DNMT1 and EZH2 in K562 and LAMA84 following 24 hours treatment with the indicated doses of panobinostat (PS). The levels of β-actin served as the loading control. caspase-8 / cleaved caspase-8 / Sp1; PubMed: 27738323 Oncotarget The indicated MM cell lines were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of caspase-8, cleaved caspase 8 and Sp1 were analyzed by Western blotting. c-Myc / IRF4; PubMed: 27738323 Oncotarget RPMI8226 cells were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of cMyc and IRF4 were analyzed by Western blotting. Ac-H3 / cleaved caspase-3 / CCND1 / ID1 / ID2 / ID3 / ID4 / Synaptophysin / NeuroD1; PubMed: 28915627 Oncotarget Immunoblotting of whole cell lysates prepared from MB cells treated with panobinostat. The representative western blot result shows panobinostat clearly regulated acetyl-Histone H3 (Ac-H3), cleaved caspase-3, CCND1, IDs, synaptophysin and NeuroD1. RAD51 / BRCA1 / CHK1 / RPL13a; PubMed: 24244429 PLoS One CTS, OCI-AML3 or U937 AML cells were treated with variable concentrations of panobinostat for 48 h. Whole cell lysates were subjected to Western blotting to measure protein levels for BRCA1, CHK1, and RAD51 in the cells. H3K9AC / H3K18AC / H3K56AC / H3 / H4K8AC / H4K16AC / H4 / p21 / p27 / cleaved PARP; PubMed: 31071955 Int J Mol Sci Immunoblot analyses of histone acetylation (H3K9AC, H3K18AC, H3K56AC, H4K8AC and H4K16AC), cell cycle arrest (p27 and p27) and apoptotic-related protein (C-Caspase 3 and C-PARP) expression following various panobinostat treatments for 6 h and 24 h on K562 cells. H3, H4 and GAPDH immunoblots served as internal controls.	19279403 27738323 28915627 24244429 31071955
Immunofluorescence	Synaptophysin / NACM; PubMed: 28915627 Oncotarget Panobinostat treated cells are positive for (B) synaptophysin (red) and (C) NCAM (red). Scale bars, 50 μm. α-tubulin / Acetyl-α-tubulin; PubMed: 29983882 Oncotarget CLBL-1 cells were treated with 10 nM of panobinostat for 24 h and then microtubules were visualized by immunofluorescence labeling using antibodies against tubulin and acetylated tubulin (ac-tubulin) using the appropriate excitation and emission filters as described in the material and methods section. Representative microphotographs with tubulin and ac-tubulin labeling (green) and DAPI stained-nuclei (blue) at 100× magnification are shown. Scale bar, 5 μm. BiP; PubMed: 23544167 Transl Oncol Immunofluorescence analysis of BiP after 24 and 48 hours of treatment in HepG2 (upper panel) and Hep3B (lower panel) cells with 0.1 µM panobinostat and 10 nM thapsigargin, showing an increase and a different protein distribution in panobinostat-treated cells, comparable to 10 nM thapsigargin effect, used as a positive control. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm. ATF4; PubMed: 23544167 Transl Oncol HepG2 (left panel) and Hep3B (right panel) cells were treated for 24 and 48 hours with 0.1 µM panobinostat and the immunofluorescence results show an increase of ATF4 and its nuclear localization in both cell lines. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm. IRE1α / S724-IRE1α; PubMed: 23544167 Transl Oncol Analysis of IRE1α/XBP1 involvement. Immunofluorescence results of IRE1α and its phosphorylated form in HepG2 (A) and Hep3B (B) cell lines after 24 and 48 hours of treatment with 0.1 µM panobinostat. The results indicate that panobinostat induces an increase of both the total and the phosphorylated form of IRE1α and a spotted distribution of this protein (enlargement showed for phospho-IRE1α, B). Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.	28915627 29983882 23544167
Growth inhibition assay	Cell viability; PubMed: 27738323 Oncotarget The indicated MM cell lines were cultured in triplicate in the absence or presence of panobinostat at the indicated concentrations. After culturing for 48 hours, cell viability was measured by a WST-8 cell proliferation assay. Results were expressed as the mean +/− SD.	27738323

In vivo

In lung cancer and mesothelioma animal models, LBH589 markedly decreases tumor growth by 62%. LBH589 is equally effective in immunocompetent and severe combined immunodeficien-cymice, suggesting that the inhibition of tumor growth by LBH589 is not due to direct immunologic effects. Daily LBH589, given i.p. at 20 mg/kg for 5 days per week, leading to an average decrease in growth of 70%. Compared with the corresponding control tumors, LBH589 leads to a 53% decrease for H526-derived tumors, an 81% decrease for BK-T-derived tumors, a 76% decrease for RG-1- derived tumors, and a 70% decrease for H69-derived tumors. In contrast to the lack of tumor regression notes in NSCLC and Meso-derived xenografted tumors that are treated under identical conditions and doses, LBH589 results in dramatic tumor regression in SCLC-derived tumors and RG-1-derived tumor. ^[2]

Protocol

Cell Research:^[1]	- Collapse Cell lines: MOLT-4 cell lines and Reh (pre-B cells) Concentrations: 50 nM Incubation Time: 48 hours Method: Untreated and LBH589-treated cells [human Ph- acute lymphoblastic leukemia MOLT-4 (T cells) and Reh (pre-B cells)] are stained with annexin V and propidium iodide using annexin V-FITC apoptosis detection kit I. The percentage of apoptotic and nonviable cells is determined by flow cytometry. At least 5 × 10⁴ cells are collected with a CyAn ADP Violet cytometer. Percentage apoptosis is calculated considering all the annexin V-positive plus the annexin V/PI-positive cells; percentage loss of cell viability is calculated considering all the annexin V-positive plus the PI-positive and the annexinV/PI-positive cells. (Only for Reference)
Animal Research:^[2]	- Collapse Animal Models: Severe combined immunodeficiency (SCID) mice with M30 (10⁷ cells) or A549 (5 × 10⁶ cells), H69 (2.5 × 10⁶ cells), BK-T (6.5 × 10⁶), H526 (10 × 10⁶), and RG1 (10 × 10⁶) cells Formulation: Dextrose 5% in water Dosages: 10 mg/kg, 20 mg/kg Administration: Administered via i.p. injection (Only for Reference)

Cell Research:^[1]

- Collapse

Cell lines: MOLT-4 cell lines and Reh (pre-B cells)
Concentrations: 50 nM
Incubation Time: 48 hours
Method: Untreated and LBH589-treated cells [human Ph- acute lymphoblastic leukemia MOLT-4 (T cells) and Reh (pre-B cells)] are stained with annexin V and propidium iodide using annexin V-FITC apoptosis detection kit I. The percentage of apoptotic and nonviable cells is determined by flow cytometry. At least 5 × 10⁴ cells are collected with a CyAn ADP Violet cytometer. Percentage apoptosis is calculated considering all the annexin V-positive plus the annexin V/PI-positive cells; percentage loss of cell viability is calculated considering all the annexin V-positive plus the PI-positive and the annexinV/PI-positive cells.
(Only for Reference)

Animal Research:^[2]

- Collapse

Animal Models: Severe combined immunodeficiency (SCID) mice with M30 (10⁷ cells) or A549 (5 × 10⁶ cells), H69 (2.5 × 10⁶ cells), BK-T (6.5 × 10⁶), H526 (10 × 10⁶), and RG1 (10 × 10⁶) cells
Formulation: Dextrose 5% in water
Dosages: 10 mg/kg, 20 mg/kg
Administration: Administered via i.p. injection
(Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	69 mg/mL (197.46 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+48% PEG 300+2% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Panobinostat (LBH589) SDF

Molecular Weight	349.43
Formula	C₂₁H₂₃N₃O₂
CAS No.	404950-80-7
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	NVP-LBH589

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03632317	Withdrawn	Drug: Panobinostat\|Drug: Everolimus	Glioma\|Diffuse Intrinsic Pontine Glioma	University of Michigan Rogel Cancer Center	October 2019	Phase 2
NCT03982134	Withdrawn	Drug: PDR001\|Drug: Panobinostat	Melanoma\|Non Small Cell Lung Cancer	Muhammad Furqan\|Novartis Pharmaceuticals\|University of Iowa	September 2019	Phase 1
NCT03515915	Recruiting	--	Patients With Recurrent or Refractory Multiple Myeloma	University Hospital Montpellier\|Poitiers University Hospital	April 23 2018	--

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How to reconstitute the compound for in vivo mice study?
Answer:
We recommend the vehicle is 2 % DMSO, 2 % Tween 80, 48%PEG300, 48% water. The compound is first dissolved in DMSO, then add Tween, PEG300, water in sequence.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Selective HDAC Inhibitor

RGFP966 : HDAC3-selective, IC50=80 nM.
Selective HDAC Inhibitor

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
Most Potent HDAC Inhibitor

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA-approved HDAC Inhibitor

Vorinostat (SAHA, MK0683) : Approved by FDA for cutaneous T cell lymphoma.
Newest HDAC Inhibitor

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

Related HDAC Products

LMK-235 ^New

LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.
CAY10603 ^New

CAY10603 is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
Domatinostat (4SC-202,Domatinostat) ^New

4SC-202 is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
Vorinostat (SAHA, MK0683)

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.
Entinostat (MS-275)

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
Trichostatin A (TSA)

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Romidepsin (FK228, Depsipeptide)

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
RGFP966

RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.
Tubastatin A

Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold).
Mocetinostat (MGCD0103)

Mocetinostat (MGCD0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Panobinostat (LBH589)

Cited by 209 Publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Panobinostat (LBH589) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Choose Your Country or Region

By Signaling Pathways

By product type

Panobinostat (LBH589)

Cited by 209 Publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Panobinostat (LBH589) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)